497 related articles for article (PubMed ID: 33027785)
21. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
22. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
[TBL] [Abstract][Full Text] [Related]
23. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
[TBL] [Abstract][Full Text] [Related]
24. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
26. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
Hay M; Leguy S; Cahagne V; Lassalle N; Le Page E; Michel L
Rev Neurol (Paris); 2024 Jun; 180(6):565-567. PubMed ID: 38429158
[No Abstract] [Full Text] [Related]
27. Seroconversion of JCV antibodies is strongly associated to natalizumab therapy.
Fragoso YD; Brooks JBB; Eboni ACB; Fezer L; da Gama PD; Gomes S; Gonçalves MVM; Machado SN; Morales RR; Pimentel MLV; Ruocco HH; Santos GA; Scherpenhuijzen S; Sousa NAC
J Clin Neurosci; 2019 Mar; 61():112-113. PubMed ID: 30396814
[TBL] [Abstract][Full Text] [Related]
28. Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis.
Branco LP; Adoni T; Apostolos-Pereira SL; Brooks JBB; Correa EC; Damasceno CA; Eboni ACB; Fezer L; Gama PDD; Goncalves MVM; Gomes S; Grzesiuk AK; Mendes MF; Morales RR; Muniz A; Parolin MFK; Pimentel MLV; Ribeiro MC; Santos GACD; Sato HK; Scherpenhuijzen SB; Scorcine C; Siquineli F; Sousa NAC; Varela DL; Winckler TCA; Fragoso YD
Arq Neuropsiquiatr; 2018 Sep; 76(9):588-591. PubMed ID: 30365621
[TBL] [Abstract][Full Text] [Related]
29. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
[TBL] [Abstract][Full Text] [Related]
30. Improving risk-stratification of natalizumab-associated PML.
Tugemann B; Berger JR
Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
[TBL] [Abstract][Full Text] [Related]
31. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
[TBL] [Abstract][Full Text] [Related]
32. Rates of John Cunningham virus seroconversion greatly reduced in natalizumab-treated patients during COVID-19-related lockdowns.
Dwyer C; Sharmin S; Kalincik T
Eur J Neurol; 2024 Jan; 31(1):e16059. PubMed ID: 37707348
[TBL] [Abstract][Full Text] [Related]
33. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
[TBL] [Abstract][Full Text] [Related]
34. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
[No Abstract] [Full Text] [Related]
35. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
36. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
Barroso B; Miquel M; Marasescu R; Demasles S; Krim E; Bonnan M
Mult Scler Relat Disord; 2015 Jul; 4(4):380-2. PubMed ID: 26195060
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
Clerico M; Artusi CA; Di Liberto A; Rolla S; Bardina V; Barbero P; De Mercanti SF; Durelli L
Expert Opin Drug Saf; 2017 Aug; 16(8):963-972. PubMed ID: 28641055
[TBL] [Abstract][Full Text] [Related]
39. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
40. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
Havla J; Berthele A; Kümpfel T; Krumbholz M; Jochim A; Kronsbein H; Ryschkewitsch C; Jensen P; Lippmann K; Hemmer B; Major E; Hohlfeld R
Mult Scler; 2013 Aug; 19(9):1213-5. PubMed ID: 23124790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
